TABLE. Hepatitis C virus clearance cascade, by selected demographics — United States, 2013–2022.
| Characteristic | No. of persons at clearance cascade step |
||||
|---|---|---|---|---|---|
| Ever infected* | Viral testing† (%)§ | Initial infection† (%)§ | Cured or cleared† (%)§ | Persistent infection or reinfection† (%)§ |
|
|
Age group, yrs
¶
| |||||
| 0–19 |
18,035 |
15,370 (85.2) |
6,274 (40.8) |
1,581 (25.2) |
107 (6.8) |
| 20–39 |
490,190 |
434,922 (88.7) |
304,022 (69.9) |
72,362 (23.8) |
6,644 (9.2) |
| 40–59 |
738,534 |
650,353 (88.1) |
458,284 (70.5) |
167,835 (36.6) |
10,813 (6.4) |
| ≥60 |
472,319 |
419,640 (88.8) |
273,329 (65.1) |
114,995 (42.1) |
5,953 (5.2) |
|
Sex
¶
| |||||
| Male |
1,031,819 |
910,407 (88.2) |
663,711 (72.9) |
226,208 (34.1) |
17,622 (7.8) |
| Female |
682,383 |
606,891 (88.9) |
376,033 (62.0) |
130,147 (34.6) |
5,868 (4.5) |
|
Payor type
| |||||
| Medicare |
132,152 |
119,693 (90.6) |
76,719 (64.1) |
34,356 (44.8) |
1,993 (5.8) |
| Medicaid |
186,464 |
164,324 (88.1) |
112,654 (68.6) |
34,817 (30.9) |
2,009 (5.8) |
| Commercial |
862,905 |
783,199 (90.8) |
496,429 (63.4) |
196,789 (39.6) |
15,125 (7.7) |
| Other (self-pay or client bill) |
386,755 |
333,335 (86.2) |
258,425 (77.5) |
58,548 (22.7) |
2,306 (3.9) |
| Unspecified | 151,217 | 120,041 (79.4) |
97,855 (81.5) |
32,297 (33.0) |
2,085 (6.5) |
* The ever infected category was assessed during the baseline period of January 1, 2013–December 31, 2021.
† The viral testing, initial infection, cured or cleared, and persistent infection or reinfection categories were assessed during the follow-up period of January 1, 2013–December 31, 2022.
§ Conditional proportion based on immediately preceding column.
¶ Age and sex weren’t reported for 415 and 5,291 persons, respectively, in the ever infected category.